Genomic Testing with Oncotype DX Provides Prognostic Information in Stage IV Breast Cancer

Posted on June 4th, 2013 by

Among women with Stage IV, estrogen receptor-positive breast cancer, the Oncotype DX® breast cancer test provided information about cancer prognosis; this may help guide treatment decisions. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO).

The Oncotype DX breast cancer test evaluates the activity of certain genes in a sample of tumor tissue. The test provides information about the likelihood of chemotherapy benefit and the risk of cancer recurrence for women with early-stage, hormone receptor-positive, invasive breast cancer. The Recurrence Score that is generated by the test ranges from 0 to 100, with higher scores indicating a higher risk of recurrence. A version of the test is also available for women with ductal carcinoma in situ (DCIS) of the breast.

To assess the Oncotype DX test among women with advanced breast cancer, researchers evaluated 102 women with Stage IV breast cancer.

  • 23% of the women had a low Recurrence Score (<18), 28% had an intermediate Recurrence Score (18-30), and 49% had a high Recurrence Score (31 or higher).
  • Among women with estrogen receptor-positive cancer, those with a higher Recurrence Score experienced a quicker worsening of their cancer (shorter time to cancer progression).
  • Among women with cancer that was both estrogen receptor-positive and HER2-negative, a higher Recurrence Score was linked with shorter overall survival.

These results suggest that the Oncotype DX breast cancer test provides information about the prognosis of Stage IV, estrogen receptor-positive breast cancer. Additional research would help to determine whether women who have a particularly poor prognosis based on the test benefit from more aggressive treatment.

Reference: King TA, Lyman JP, Gonen M et al. prognostic impact of the 21-gene recurrence score in patients presenting with stage IV breast cancer. Presented at the 49th Annual Meeting of the American Society of Clinical Oncology. May 31-June 4, 2013; Chicago, IL. Abstract 507.

Copyright © 2013 CancerConsultants. All Rights Reserved.

Tags: Breast Cancer, Metastatic Breast Cancer, News

You must be logged-in to the site to post a comment.